Get the Stockscreener App
42.91
0.52%
0.22
After Hours:
43.03
0.12
+0.28%
Tempus Ai Inc stock is traded at $42.91, with a volume of 5.39M.
It is up +0.52% in the last 24 hours and down -23.57% over the past month.
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
See More
Previous Close:
$42.69
Open:
$43.8
24h Volume:
5.39M
Relative Volume:
0.87
Market Cap:
$7.73B
Revenue:
$1.36B
Net Income/Loss:
$-302.91M
P/E Ratio:
-24.97
EPS:
-1.7182
Net Cash Flow:
$-219.93M
1W Performance:
-11.36%
1M Performance:
-23.57%
6M Performance:
-35.77%
1Y Performance:
-33.46%
1-Day Range:
$42.01
$44.38
1-Week Range:
$42.01
$50.01
52-Week Range:
$41.73
$104.32
Tempus Ai Inc Stock (TEM) Company Profile
Name
Tempus Ai Inc
Sector
Industry
Phone
800-976-5448
Address
600 WEST CHICAGO AVENUE, CHICAGO
Compare TEM vs VEEV, BTSG, HQY, TXG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
42.91 | 7.69B | 1.36B | -302.91M | -219.93M | -1.7182 |
VEEV
Veeva Systems Inc
|
194.46 | 30.25B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
71.98 | 14.31B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
99.05 | 7.91B | 1.34B | 230.70M | 440.96M | 2.6695 |
TXG
10 X Genomics Inc
|
45.92 | 5.87B | 638.78M | -22.66M | 122.18M | -0.1744 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Underperform |
| Apr-13-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-19-26 | Initiated | Mizuho | Outperform |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-21-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-20-25 | Initiated | Canaccord Genuity | Buy |
| Sep-02-25 | Initiated | H.C. Wainwright | Buy |
| Apr-21-25 | Initiated | BTIG Research | Buy |
| Feb-25-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-12-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-05-25 | Resumed | TD Cowen | Buy |
| Dec-13-24 | Initiated | Wolfe Research | Outperform |
| Dec-09-24 | Initiated | Guggenheim | Buy |
| Nov-11-24 | Downgrade | Stifel | Buy → Hold |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-12-24 | Initiated | Piper Sandler | Neutral |
| Jul-09-24 | Initiated | BofA Securities | Buy |
| Jul-09-24 | Initiated | JP Morgan | Overweight |
| Jul-09-24 | Initiated | Longbow | Buy |
| Jul-09-24 | Initiated | Loop Capital | Buy |
| Jul-09-24 | Initiated | Morgan Stanley | Overweight |
| Jul-09-24 | Initiated | Needham | Buy |
| Jul-09-24 | Initiated | Stifel | Buy |
| Jul-09-24 | Initiated | TD Cowen | Buy |
| Jul-09-24 | Initiated | William Blair | Outperform |
View All
Tempus Ai Inc Stock (TEM) Latest News
Artificial Intelligence Stocks To Keep An Eye OnJuly 27th - MarketBeat
Tempus AI Stock (TEM) Opinions on Personalis Acquisition and Analyst Upgrades - Quiver Quantitative
Tempus AI to Acquire Personalis in $1.5 Billion Deal, Deepening Its Foothold in Cancer Monitoring - Oncodaily
Tempus AI Inc (TEM) Balance Sheet - TradingKey
AI Stocks: Why Tempus AI (NASDAQ:TEM), Recursion Pharmaceuticals (NASDAQ:RXRX) and Schrodinger (NASDAQ:SDGR) Are in Focus - Kalkine Media
Tempus AI Inc (TEM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alan Tan: Highlighting Ultrasensitive MRD Detection with Tempus AI at KCRS26 - Oncodaily
136,636 Shares in Tempus AI, Inc. $TEM Acquired by Aristotle Atlantic Partners LLC - MarketBeat
Tempus AI (NASDAQ:TEM) Shares Fall 19% as Attention Turns to Merger Collar - TechStock²
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Brainsway (BWAY) and Argenx Se (ARGX) - The Globe and Mail
Tempus AI Inc (TEM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tempus AI Inc (TEM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tempus AI Inc|Price:42.690|Chg%:-3.320 - TradingKey
Tempus AI (NASDAQ:TEM) Upgraded to Hold at Wall Street Zen - MarketBeat
Tempus AI stock: H.C. Wainwright reiterates Buy on MRD expansion - Investing.com UK
Tempus AI buys Personalis for $1.5B; UCSF Health, Kleiner Perkins and Doerr Capital launch health AI accelerator; Candid Health raises $120M - VatorNews
Tempus AI Stock Before Q2 Earnings Release: To Buy, Hold or Sell? - Yahoo Finance
Tempus to acquire Personalis in $1.5 billion deal to expand MRD capabilities - DOTmed
Tempus AI stock: H.C. Wainwright reiterates Buy on MRD expansion By Investing.com - Investing.com Canada
GC Wealth Management RIA LLC Cuts Position in Tempus AI, Inc. $TEM - MarketBeat
Cathie Wood buys $8.7 million of beaten-down AI stock - thestreet.com
Artificial Intelligence Stocks To Follow NowJuly 23rd - MarketBeat
Tempus AI (TEM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo! Finance Canada
Tempus AI (TEM) Expected to Announce Earnings on Thursday - MarketBeat
Tempus AI (TEM) Unveils National Rollout of Pharmacogenomics Tes - GuruFocus
Tempus AI Expands Cancer Platform With Launch of ArteraAI Prostate Test For Metastatic Patients - Stocktwits
Tempus makes $1.5B bet to corner cancer-test market - thestreet.com
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring - Sahm
What's behind Tempus AI's latest 3.5% stock pullback? - Traders Union
Best Artificial Intelligence Stocks To Follow TodayJuly 22nd - MarketBeat
Why is Tempus AI stock sliding today? By Investing.com - Investing.com Canada
Tempus AI launches pharmacogenomics testing nationwide By Investing.com - Investing.com Nigeria
Tempus AI launches pharmacogenomics testing nationwide - Investing.com
Tempus Launches Test for Therapies With Nearly 30% Severe Toxicities - Stock Titan
Tempus AI to Acquire Cancer Diagnostics Firm Personalis for approximately $1.5 Billion, Targeting MRD Market Leadership - finance.biggo.com
Tempus AI (TEM) On Its Personalis Deal And Whether The Bull Case Is Priced In - Yahoo Finance
Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks - Sahm
Tempus to acquire Personalis, Inc. (PSNL) in cash and stock merger - Stock Titan
Tempus AI: Buy Rating Reaffirmed as Personalis Deal Strengthens MRD Position; $75 Price Target Maintained - TipRanks
Why Is Tempus AI Stock Volatile Tuesday?Personalis (NASDAQ:PSNL), Tempus AI (NASDAQ:TEM) - Benzinga
TEM, PSNL stocks are falling — why Morgan Stanley still likes Tempus AI’s Personalis deal - MSN
Tempus AI buys Personalis for $1.5 billion - grafa.com
Artificial Intelligence Stocks To Add to Your WatchlistJuly 21st - MarketBeat
Tempus AI Buys Personalis for $1.5B to Boost Cancer Monitoring - Medical Device and Diagnostic industry
Tempus AI to Acquire Personalis for $1.5 Billion to Expand Precision Oncology Platform - HLTH
Tempus AI Stock Short Interest Falls to 33.94% - Quiver Quantitative
Tempus AI is acquiring cancer-monitoring firm Personalis in a $1.5 billion stock deal - qz.com
Tempus AI Acquires Personalis: Why Both Stocks Are A Buy Now (NASDAQ:TEM) - Seeking Alpha
Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion - Yahoo Finance
Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal - Yahoo Finance
Tempus AI snaps up genomics partner Personalis for $1.5 billion - The Pharma Letter
Tempus Ai Inc Stock (TEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.67%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):